Therefore, we were only able to evaluate the safety profiles of SGLT2 inhibitors in all Japanese patients with DM; however, we confirmed that the results of the sub-analysis of patients with type 2 DM only were consistent with those of the main analyses among all patients with DM (Supplementary Table S1). The gene discussed is SLC5A2; the disease is diabetes mellitus.